Introduction {#S0001}
============

Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related death in the world.[@CIT0001] In 2012, China alone accounted for \~50% of new liver cancer cases and deaths worldwide,[@CIT0002] with 5-year survival rates only reaching 10.1%.[@CIT0003]

HCC is a common pathological type of liver cancer,[@CIT0004] and chronic hepatitis B virus (HBV) infection is the most common cause of HCC in the Chinese population.[@CIT0005] In China, the Guangxi Zhuang Autonomous Region has a higher prevalence of HBV infection and aflatoxin B1 exposure compared with other provinces, and subsequently higher morbidity and mortality due to HCC.[@CIT0006]--[@CIT0008]

For patients with solitary HCC, surgical resection is potentially curative.[@CIT0009] However, prognosis is still not satisfactory, because of high postoperative recurrence and metastasis.[@CIT0010]--[@CIT0014] A major obstacle to choosing better curative procedures is the lack of tools for preoperatively determining the aggressiveness of HCC.

Researchers have attempted different methods for predicting the prognosis of HCC cohorts.[@CIT0015]--[@CIT0019] Computed tomography (CT) is a noninvasive imaging modality that is routinely used for diagnosis, treatment planning, and monitoring of liver cancer, CT is the conventional low cost standard modality for diagnosing HCC.

The gene expression patterns in tumor tissue can portend patients' therapeutic response and prognosis[@CIT0020] and may be predicted by imaging traits.[@CIT0021] For example, moving toward personalized medicine, Segal et al[@CIT0021] reported that a combination of 28 CT imaging traits in HCC could be used to reconstruct 78% of global HCC gene-expression profiles that reflected patient prognosis. Another study showed that gene-expression profiles of cancer can suggest tumor biological behavior and clinical course, and can be mapped to corresponding tumor-imaging signatures.[@CIT0022] An imaging feature identified as a powerful prognostic biomarker can provide significant additional information in colorectal cancer.[@CIT0023]

Similarly, studies have indicated that CT imaging can be used as a significant predictor of early recurrence in HCC after resection (within 1 year),[@CIT0024] as well as poor overall survival (OS) in HCC patients after surgical treatment or liver transplantation.[@CIT0025] The underlying mechanisms of disease-free survival (DFS) and OS are likely associated with the biological aggressiveness of the tumor.[@CIT0026] Yet, it is not known whether CT signatures may be a biomarker of DFS or OS in HBV-related solitary HCC.

Microvascular invasion (MVI) is an important independent risk factor of recurrence after surgical treatment of HCC.[@CIT0027],[@CIT0028] Recent studies suggest that non-smooth tumor margin[@CIT0029]--[@CIT0033] may be used to predict MVI. However, the mechanism of non-smooth tumor margin that drives MVI remains unclear. One of our previous studies showed that non-smooth tumor margin correlated with postoperative HCC recurrence.[@CIT0034] A subgroup analysis of negative MVI is used to explore possible mechanisms of non-smooth tumor margin.

Recent studies showed that postoperative pathological variables, including histological differentiation,[@CIT0035] satellite node of tumor[@CIT0036] and liver capsular invasion,[@CIT0037],[@CIT0038] were independent indicators of postoperative HCC recurrence. To improve the accuracy of preoperative prediction model, pathological variables would be better to correct the conclusions of preoperative CT by multivariate analysis. In addition, a postoperative predictive model was established to improve treatment strategies for the patients who had already undergone surgery.

To improve the preoperative surgical planning of patients with HBV-related solitary HCC, this retrospective study investigated the prognostic value of CT signatures. The clinical data, pathological results, and serological results were assessed as secondary endpoints.

Methods {#S0002}
=======

Patients {#S0002-S2001}
--------

The present study was approved by the Institutional Review Board of Affiliated Tumor Hospital of Guangxi Medical University and written informed consent was obtained from all individuals in this research project. This study initially included 166 patients (135 men and 31 women; aged 24--79 y, mean age 48.0 y) with operable HCC (ie, meeting the Barcelona Clinic Liver Cancer requirements for operability based on imaging),[@CIT0039] who underwent preoperative CT in our hospital from 15 November 2013 through 15 May 2015. The follow-up information was obtained from the medical records of our hospital. All patients signed informed consent forms to undergo CT and curative resection.

Follow-ups (closed on 5 June 2017) confirmed recurrence and metastases of HCC by pathological or radiological diagnosis. OS was defined as the time from surgery to the date of death or last follow-up. DFS was the time from surgery to the date of recurrence, metastasis, death, or last follow-up.

All patients met the following criteria for inclusion in this study: no cancer-related treatment or biopsy performed on a solitary HCC prior to the CT imaging scan, and preoperative CT performed ≤1 month before surgery; underwent radical resection, with HCC confirmed by histopathology; without macrovascular invasion or metastasis on preoperative CT imaging; positive for serum HBV surface antigen; without hepatitis C virus (HCV) infection; and Child-Pugh class A, according to the Child-Pugh liver disease classification.

CT imaging protocol {#S0002-S2002}
-------------------

CT images of the liver were performed on a 64-MDCT scanner (SOMATOM Sensation 64, Siemens, Germany) equipped with the following parameters: z-axis modulation; spiral pitch 1; 5-mm section thickness; 2-mm reconstruction gap; field of view 311 mm; 120 kVp; 230 mA; and a standard reconstruction algorithm. Nonionic contrast medium (iopromide, 300 mgI/mL) was administered at a total dose of 100 mL with an injection rate of 3 mL/s. For the hepatic arterial and portal venous phases, scanning began \~30--35 and 65--70 seconds, respectively, after injection of the contrast medium. Equilibrium phase images were acquired about 180--200 seconds after injection of the contrast medium. The scanning range included the entire liver while the patients held their breath. Coronal and sagittal images were reconstructed with a 5-mm section thickness.

Image evaluation {#S0002-S2003}
----------------

The basic imaging traits were the absence or presence of the following: radiologic evidence of liver cirrhosis; according to previous studies, liver cirrhosis could be diagnosed by CT with a sensitivity of 84%, a specificity of 100%, and an accuracy of 94%;[@CIT0040] splenomegaly; ascites; esophageal and gastric varices; peritumoral enhancement;[@CIT0029] necrosis; and radiographic venous invasion (RVI; [Figure 1](#F0001){ref-type="fig"}). According to previous studies,[@CIT0024],[@CIT0025] RVI was redetermined according to 3 imaging features (defined below): internal vessels, hypodense halo, and tumor-liver difference. Internal vessels are observed as linear vessels enhancement within the tumor on venous phase imaging. A hypodense halo is a rim of hypodensity, partially or completely surrounding the tumor. The tumor-liver difference is a focal or circumferential sharp transition in attenuation between the tumor and the adjacent liver parenchyma without a hypodense halo.Figure 1RVI is determined by 3 traits in patients with HCC.**Abbreviations:** HCC, hepatocellular carcinoma; RVI, radiographic venous invasion.

In addition, imaging data of the following tumor characteristics were noted: location (left, right, or both lobes); size (maximal diameter of the largest cross section \<10 cm or ≥10 cm); margin (smooth or non-smooth margin; [Figure 2](#F0002){ref-type="fig"});[@CIT0029] and capsule (complete, incomplete, or without tumor capsule).[@CIT0029]Figure 2Illustration shows 2 patterns of tumor margins (drawing by Zhang).

The imaging features of each patient were recorded as the consensus of 2 experienced radiologists (Wei Zhang and Lijuan Liu, with 10 and 6 years of experience in reading liver CTs, respectively). If necessary, a third radiologist joined a consensus conference.

Clinical risk factors {#S0002-S2004}
---------------------

The following potential demographic and lifestyle risk factors were analyzed: age (≤60 or \>60 y); gender; ethnicity (Han or minority); body mass index (BMI, ≤25 or \>25); smoking status (none or ever); and drinking status (none or ever). In addition, the presence or absence of the following was analyzed as potential risk factors: satellite node of tumor; MVI; and liver capsular invasion. The clinical risk factors also included: histological differentiation (according to Edmondson-Steiner grading system, Grade I was considered as high differentiated, Grade II/III as moderate, and Grade IV as poor); alpha-fetoprotein (AFP; \<400 or ≥400 ng/mL); ratio of serum albumin to globulin (A/G; ≤2.5 or \>2.5); alanine aminotransferase (ALT; ≤40 or \>40 U/L); aspartate aminotransferase (AST; ≤40 or \>40 U/L); alkaline phosphatase (ALP; ≤150 or \>150 U/L); lactate dehydrogenase (LDH; ≤285 or \>285 U/L); and γ-glutamyl transferase (GGT; ≤50 or \>50 U/L).

The threshold values chosen for AFP, A/G, ALT, AST, ALP, LDH, and GGT levels were based on the normal ranges used at our institution.

Statistical analysis {#S0002-S2005}
--------------------

Survival analyses were performed using the Kaplan-Meier method with the log-rank test for different CT signatures and clinical risk factors. Cox proportional hazards regression analysis was performed to calculate the crude or adjusted hazard ratio (HR) and 95% confidence interval (CI) in univariate and multivariate survival analyses, with adjustment for CT signatures, pathological parameters, and serum indicators.

A nomogram was formulated based on the results of multivariate Cox regression analysis and using the Regression Modeling Strategy (rms) in the R software package version 3.4.0 (<http://www.r-project.org/>).[@CIT0041] A final nomogram model was based on a backward stepdown selection process using Akaike's information criterion.[@CIT0042]

A *P*-value \<0.05 was considered statistically significant. Statistical analyses were performed with SPSS version 16.0 (IBM, Chicago, IL, USA) statistical software.

Results {#S0003}
=======

Patient characteristics {#S0003-S2001}
-----------------------

A total of 157 patients (131 men and 26 women) with HBV-related HCC completed the follow-up period successfully, with a loss to follow-up rate of 5.4%. Of the 157 patients, 42 patients (26.8%) experienced recurrence and metastasis, of whom 10 (6.4%) died from cancer. The 42 cases of recurrence or metastasis consisted specifically of the following: 32 (76.2%) intrahepatic recurrence; 4 (9.5%) extrahepatic metastases (2 in the lung, 1 on the peritoneum, and 1 in lymph nodes); and 6 (14.3%) with both intrahepatic recurrence and extrahepatic metastases. These cases were treated as follows: 19 repeat curative resection; 6 radiofrequency ablation; 8 transcatheter arterial chemoembolization; 3 sorafenib; 5 transcatheter arterial chemoembolization and sorafenib; and 1 without any treatment. Liver cirrhosis was confirmed by histopathological examination and radiology.

Prognostic risk factors for OS and DFS {#S0003-S2002}
--------------------------------------

The univariate analysis indicated that liver capsular invasion and larger tumor size were significantly associated with poor OS ([Table 1](#T0001){ref-type="table"}). However, in the multivariate analysis, it was found that the analyzed prognostic risk factors were not significantly associated with OS.Table 1Univariate and multivariate analyses of preoperative factors associated with overall survivalPt, *n*Events, *n*UnivariateMultivariateLog-rank *P*Log-rank *P*Clinical characteristicsAge, y≤6014190.978\>60161GenderMale13170.255Female263EthnicityHan8340.390Minority746BMI≤2511690.237\>25411Smoking statusNone11190.165Ever461Drinking statusNone11090.161Ever471CT signaturesCirrhosisAbsent3720.7800.887Present1208SplenomegalyAbsent6950.6900.176Present885AscitesAbsent14690.7870.154Present111PositionsLeft lobe3820.8080.292Right lobe1107Both91Tumor size, cm\<1014260.0000.143≥10154Peritumoral enhancementAbsent142100.2940.169Present150NecrosisAbsent6330.4960.186Present947RVIAbsent12170.5400.129Present363Tumor marginSmooth9940.1050.128Non-smooth586Radiological capsuleComplete7540.4350.326Incomplete505Absent321Esophageal, gastric varicesAbsent14180.3400.142Present162Pathological evidenceHistological differentiationWell1100.2350.583Moderate753Poor717Satellite nodeAbsent143100.3200.587Present140MVI Absent10240.0740.127Present556Liver capsular invasionAbsent8120.0400.117Present768Serum parametersAFP, ng/mL\<4009740.1390.134≥400606A/G≤2.514890.4490.378\>2.591ALT, U/L≤402910.4920.134\>401289AST, U/L≤402510.6190.131\>401329ALP, U/L≤15013090.5800.127\>150271LDH, U/L≤2859040.2540.123\>285676GGT, U/L≤508460.6560.132\>50734[^2]

In the 157 patients followed for \>2 years, the univariate analysis indicated that the significant prognostic factors of worse DFS were the following ([Table 2](#T0002){ref-type="table"}; [Figure 3](#F0003){ref-type="fig"}): larger tumor size; positive RVI; non-smooth tumor margin; and positive MVI.Table 2Univariate analysis of preoperative factors associated with disease-free survivalPt, *n*Events, *n*Log-rank *P*HR (95% CI)Clinical characteristicsAge, year≤60141380.8651\>601640.916 (0.327--2.566)GenderMale131340.6741Female2681.177 (0.545--2.545)EthnicityHan83230.8011Minority74190.926 (0.504--1.700)BMI≤25116340.2331\>254180.631 (0.292--1.364)Smoking statusNone111290.9931Ever46131.003 (0.521--1.929)Drinking statusNone110320.2371Ever47100.657 (0.323--1.336)CT signaturesCirrhosisAbsent3770.2041Present120351.673 (0.743--3.769)SplenomegalyAbsent69170.5831Present88251.186 (0.640--2.196)AscitesAbsent146380.3961Present1141.550 (0.552--4.346)PositionsLeft lobe3870.4211Right lobe110331.693 (0.749--3.829)Both921.306 (0.271--6.291)Tumor size, cm\<10142350.0221≥101572.484 (1.101--5.605)Peritumoral enhancementAbsent142380.8671Present1540.917 (0.327--2.569)NecrosisAbsent63160.7281Present94261.116 (0.598--2.080)RVIAbsent121260.0021Present36162.527 (1.353--4.722)Tumor marginSmooth99170.0001Non-smooth58253.029 (1.631--5.623)Radiological capsuleComplete75170.5381Incomplete50151.390 (0.694--2.783)Absent32101.441 (0.659--3.147)Esophageal, gastric varicesAbsent141350.1041Present1671.925 (0.854--4.340)Pathological evidenceHistological differentiationWell1120.7031Moderate75191.528 (0.356--6.562)Poor71211.763 (0.413--7.519)Satellite nodeAbsent143390.7271Present1430.813 (0.251--2.633)MVIAbsent102190.0021Present55232.724 (1.480--5.012)Liver capsular invasionAbsent81200.9491Present76220.981 (0.535--1.797)Serum parametersAFP, ng/mL\<40097220.0981≥40060201.650 (0.900--3.025)A/G≤2.5148380.1171\>2.5942.214 (0.788--6.221)ALT, U/L≤402970.7301\>40128351.152 (0.512--2.593)AST, U/L≤402560.7261\>40132361.165 (0.491--2.766)ALP, U/L≤150130350.8991\>1502770.949 (0.421--2.141)LDH, U/L≤28590220.3341\>28567201.342 (0.732--2.461)GGT, U/L≤5084220.8111\>5073201.076 (0.587--1.971)[^3] Figure 3DFS curves of 157 patients with HBV-related HCC who underwent curative resection.**Abbreviations:** HCC, hepatocellular carcinoma; MVI, microvascular invasion; RVI, radiographic venous invasion.

The following were not significant prognostic factors ([Table 2](#T0002){ref-type="table"}): age; gender; ethnicity; BMI; smoking or drinking status; radiologic evidence of liver cirrhosis; splenomegaly; ascites; esophageal and gastric varices; tumor location; peritumoral enhancement; necrosis; tumor capsule incomplete or without tumor capsule; moderate or poor tumor differentiation; satellite node of tumor; capsular invasion of the liver; or elevated AFP, A/G, ALT, AST, ALP, LDH, and GGT levels.

After adjusting for risk factors in the Cox proportional hazards regression analysis, the following were significant prognostic risk factors of DFS ([Table 3](#T0003){ref-type="table"}): larger tumor size; positive RVI; non-smooth tumor margin; or positive MVI. RVI and MVI were analyzed separately because of collinearity between RVI and MVI.Table 3Multivariate analysis of preoperative factors associated with disease-free survivalAdjusted Log-rank *P*Adjusted HR (95% CI)**CT signatures**CirrhosisAbsent0.1141Present2.347 (0.814--6.769)SplenomegalyAbsent0.9001Present0.953 (0.448--2.027)AscitesAbsent0.0731Present3.436 (0.890--13.264)PositionsLeft lobe0.7131Right lobe1.438 (0.513--4.034)Both0.908 (0.158--5.217)Tumor size, cm\<100.0201≥103.875 (1.242--12.089)Peritumoral enhancementAbsent0.8521Present1.116 (0.352--3.539)NecrosisAbsent0.1601Present0.541 (0.230--1.274)RVI^†^Absent0.0211Present2.589 (1.157--5.795)Tumor marginSmooth0.0361Non-smooth2.296 (1.054--5.003)Radiological capsuleComplete0.9801Incomplete1.070 (0.458--2.497)Absent0.977 (0.391--2.441)Esophageal, gastric varicesAbsent0.0671Present2.596 (0.937--7.193)Pathological evidenceHistological differentiationWell0.9551Moderate1.263 (0.241--6.607)Poor1.284 (0.257--6.401)Satellite nodeAbsent0.3531Present0.510 (0.123--2.115)MVI^†^Absent0.0181Present2.531 (1.169--5.481)Liver capsular invasionAbsent0.1841Present0.598 (0.280--1.277)Serum parametersAFP, ng/mL\<4000.6201≥4001.213 (0.565--2.606)A/G≤2.50.1981\>2.52.264 (0.652--7.857)ALT, U/L≤400.2401\>402.192 (0.592--8.120)AST, U/L≤400.4111\>400.580 (0.158--2.129)ALP, U/L≤1500.5941\>1500.774 (0.302--1.984)LDH, U/L≤2850.3481\>2851.438 (0.673--3.070)GGT, U/L≤500.4281\>500.733 (0.341--1.580)[^4][^5]

The following were not significantly associated with DFS ([Table 3](#T0003){ref-type="table"}): radiologic evidence of liver cirrhosis; splenomegaly; ascites; esophageal or gastric varices; tumor location; peritumoral enhancement; necrosis; tumor capsule incomplete or without tumor capsule; pathological parameters except for MVI; and elevated serum levels of parameters.

DFS of RVI, non-smooth tumor margin and tumor size in stratified analyses {#S0003-S2003}
-------------------------------------------------------------------------

With positive MVI, a positive RVI (HR 0.578; 95% CI 0.156--2.137; *P*=0.411), and non-smooth tumor margin (HR 2.103; 95% CI 0.424--10.430; *P*=0.363) were not associated with worse DFS in these HBV-related HCC patients.

With negative MVI, a positive RVI (HR, 12.750; 95% CI: 2.182--74.492; *P*=0.005) and non-smooth tumor margin (HR, 18.188; *P*=0.001; 95% CI: 3.320--99.630) were associated with poor DFS.

In stratified analyses, larger tumor size in negative MVI (HR, 2.361; *P*=0.173; 95% CI: 0.687--8.114) and in positive MVI (HR, 2.491; *P*=0.100; 95% CI: 0.840--7.387) were not associated with worse DFS in these HBV-related HCC patients.

Prognostic nomogram for DFS and validation {#S0003-S2004}
------------------------------------------

A prognostic nomogram of the preoperative CT based on the Cox regression model for DFS in the primary cohort was constructed ([Figure 4A](#F0004){ref-type="fig"}). The C-index for DFS prediction was 0.698 (95% CI: 0.655--0.741). Bootstrapping validation suggested the suitability of the prognostic model for patients with operable HCC. The calibration plot for predicting the probability of DFS at 1-, 2-, or 3-years after curative resection showed good conformity between the nomogram and the actual observation ([Figure 4B--D](#F0004){ref-type="fig"}).Figure 4Prognostic nomogram of preoperative CT for DFS in patients with HBV-related HCC after curative resection. (**A**) DFS nomogram. To use the nomogram, the value of an individual patient is located on each variable axis, and a line is drawn upward to determine the number of points received for each variable value. The sum of these numbers is located on the total point axis, and a line is drawn downward to the survival axes to determine the likelihood of 1-, 2-, and 3-year DFS. (**B**--**D**) The calibration curve of DFS at (**B**) 1-, (**C**) 2-, and (**D**) 3-years in the validation cohort. Nomogram-predicted probability of DFS is plotted on the x-axis, actual DFS is plotted on the y-axis. Size is the maximal diameter of the largest cross section; margin is the radiologic evidence of tumor margin.**Abbreviations:** CT, computed tomography; HCC, hepatocellular carcinoma; RVI, radiographic venous invasion.

A prognostic nomogram that integrated all significant independent risk factors for DFS in the primary cohort was also constructed ([Figure 5A](#F0005){ref-type="fig"}). The nomogram predicts the probability that the patient will develop recurrence or metastasis within 1-, 2-, or 3-years after curative resection. The C-index for DFS prediction was 0.728 (95% CI: 0.641--0.815). The nomogram was validated internally using bootstrapping. The model showed good validation ([Figure 5B--D](#F0005){ref-type="fig"}).Figure 5DFS nomogram for HBV-related HCC after curative resection. (**A**) Nomogram for predicting 1-, 2-, and 3-year probability of DFS in patients with HBV-related HCC after curative resection. To estimate risk, points for each variable were calculated by drawing a straight line from patient's variable value to the axis labeled "Points"; all points were summed, and a line drawn from the total point axis to the 1-, 2-, and 3-year DFS. (**B**--**D**) The calibration curve of DFS at (**B**) 1-, (**C**) 2-, and (**D**) 3-years in the validation cohort. Nomogram-predicted probability of DFS is plotted on the x-axis, actual DFS is plotted on the y-axis. Size is the maximal diameter of the largest cross section; margin is the radiologic evidencethe tumor margin.**Abbreviations:** CT, computed tomography; HCC, hepatocellular carcinoma; MVI, microvascular invasion; RVI, radiographic venous invasion.

Discussion {#S0004}
==========

In the present study, we investigated the ability of CT image characteristics to predict the prognosis of HBV-related HCC after curative resection. Preoperative multiphasic CTs of patients with operable HCC were analyzed, as well as pathology and clinical characteristics, and recurrence and metastases of HCC at follow-up. The univariate and multivariate analyses showed that radiologic evidence of positive RVI, non-smooth tumor margin (not investigated previously), and larger tumor size were significantly associated with poor DFS. Non-smooth tumor margin was an independent risk factor for recurrence and metastasis. The nomogram performed well in predicting the DFS of patients with HBV-related solitary HCC, and its prediction was supported by the calibration curve and bootstrapping validation.

Our results regarding lack of association between the prognostic risk factors and OS were not consistent with a previous study, which found radiologic evidence that positive RVI was associated with poor OS.[@CIT0025] This discrepancy may be due to differences in the inclusion criteria of the studies, that in the present study in the overall cohort there were only 10 cases of death (since the tumor was radically resected), and the follow-up time was not sufficient. A follow-up study will be necessary to confirm an association between CT features and OS in HBV-related HCC after curative resection.

In the present study, the univariate analysis indicated that liver capsular invasion was significantly associated with poor OS. This result was consistent with previous reports.[@CIT0043],[@CIT0044] Liver capsular invasion was the natural biological behavior of the tumor. However, the multivariate analysis showed that liver capsular invasion was not significantly associated with OS. This result needs to be further validated, because there were only 10 deaths in the overall cohort.

In the present study, radiologic evidence of positive RVI, non-smooth tumor margin, and larger tumor size were significantly associated with poor DFS. In other studies, investigations have shown that non-smooth tumor margin[@CIT0029] and RVI[@CIT0025] were associated with MVI. MVI has been validated as a powerful and independent predictor of recurrence after surgical treatment.[@CIT0045]--[@CIT0047]

Interestingly, in a subgroup analysis of negative MVI in the present study, a positive RVI and non-smooth tumor margin remained significantly associated with worse DFS, whereas MVI positivity was not. A possible reason is that imaging features reveal gene expression patterns of the tumor,[@CIT0020]--[@CIT0022] but not MVI itself, and may capture more phenotypes of the tumor. Other possible reasons are that the sample size of positive MVI in the present study was only 55 patients, and these cases had undergone routine antiviral therapy and chemotherapy after curative resection in our hospital. Furthermore, a non-smooth tumor margin as a significant predictor of poor DFS may be related to tumor biological aggressiveness, and multicentric HCC should be considered. One of our previous studies showed that nodular borders of non-smooth tumors are rich in pathological vessels,[@CIT0048] which may be one of the causes of recurrence and metastasis.

Numerous studies have shown that tumor size is a predictor of poor prognosis in HCC.[@CIT0025],[@CIT0047],[@CIT0049],[@CIT0050] Similarly, we found in the present study that the HR of tumors ≥10 cm for radiologic evidence of poor DFS was significantly higher than the corresponding HR of tumors \<10 cm.

In this retrospective study, we investigated whether histological MVI is an independent predictor for poor prognosis in HBV-related HCC patients. The results showed that although these patients with histological MVI had been given regular antiviral therapy and chemotherapy, histological MVI remained associated with worse DFS. Thus, the poor outcome predicted by histological MVI should be kept in mind. Poor differentiation is commonly considered to suggest a high risk for poor survival.[@CIT0051] However, our data indicated no statistical association between pathology grade and DFS. No other imaging traits, pathology, or clinical features were useful in significantly predicting DFS.

This study was limited by a small sample size, and a future study with a larger patient population is essential to validate the result. In addition, this was a single-center study, the retrospective cohort and imaging methods varied, and selection bias may exist. A third potential limitation is the use of CT, which is commonly used for HCC evaluation, but may be inferior to MRI. The fourth limitation is that MVI can predict postoperative HCC recurrence and there is a positive correlation between tumor margin and postoperative HCC recurrence, but it does not necessarily means tumor margin can predict MVI. The further study is necessary.

Conclusion {#S0005}
==========

Noninvasive preoperative CT imaging characteristics may be useful to prognosticate DFS. The nomogram was developed for predicting individual DFS in patients with HBV-related solitary HCC. Patients with HBV-related HCC with radiologic evidence of positive RVI, non-smooth tumor margin, or tumor size ≥10 cm may require more aggressive treatment (such as wide resection margins during curative resection) to reduce rates of recurrence and metastasis. However, our results still need further verification in multi-center with large sample size.
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